XBiotech Pauses Rheumatology program - The Manila Times
XBiotech halts rheumatology clinical program due to irregularities in Phase II RA study with Natrunix, failing to meet primary endpoint. Additional studies on hold pending evaluation.
Highlighted Terms
Related News
XBiotech Pauses Rheumatology program - The Manila Times
XBiotech halts rheumatology clinical program due to irregularities in Phase II RA study with Natrunix, failing to meet primary endpoint. Additional studies on hold pending evaluation.